Weill Cornell Medicine

About This Center

Weill Cornell Medicine’s world-renowned Multiple Myeloma Center is dedicated to delivering the most advanced treatment and comprehensive care for patients with all stages of multiple myeloma and related plasma cell disorders. We also treat rare plasma disorders such as amyloidosis, POEMS, light or heavy chain deposition disease and cryoglobulinemia.

We are an integrated center and have developed an outstanding multidisciplinary team that includes medical oncologists, hematologists, radiation oncologists, surgeons, radiologists, pathologists, transplant physicians, nurses and other healthcare professionals.

At the Weill Cornell Multiple Myeloma Center, we view each person as an individual, and our approach ensures that each treatment regimen is narrowly tailored to meet the unique needs of each of our patients and their families. We pride ourselves on the one-on-one relationships we develop with our patients and their loved ones, and we collaborate with referring providers to ensure that everyone is on the same page with regards to the course of treatment. Additionally, we realize that a cancer diagnosis can affect your whole life, so we provide support beyond just delivering the best medical treatment. We offer educational sessions, support groups, nutritional guidance, and more.

Myeloma Clinical Trials

PRospective Multiple Myeloma Impact Study (PROMMIS)

We are doing this study to learn if the MMprofiler genomic test can help your doctor in making decisions about your treatment.

Learn more about this trial


Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.

Learn more about this trial


BiRd vs. Rd as Initial Therapy in Multiple Myeloma

This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.

Learn more about this trial


A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma

This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma.

Learn more about this trial


Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT)

This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).

Learn more about this trial


A Phase 1/2a Study Investigating TAK-079 Administered Subcutaneously in Patients With Relapsed/Refractory Multiple Myeloma

This is a phase 1/2a study evaluating the safety, tolerability and the most appropriate dose, of TAK-079 monotherapy as treatment for patients with Relapsed/Refractory Multiple Myeloma.

Learn more about this trial


Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies.

Learn more about this trial


Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.

Learn more about this trial


A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Learn more about this trial


Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA) for Haplo-Cord Transplantation

In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes. We hypothesize that identification of a graft that is at least 5/6 matched and inherited paternal antigen (IPA) targeted (i.e., cord blood grafts share one or more IPA antigens with the prospective recipient) is more important to the outcome of haplo cord transplant than the nucleated cell dose. The identification of such a graft for a large proportion of the subjects may necessitate accepting a lower umbilical cord graft dose.

Learn more about this trial


Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

The primary objective of this study is to evaluate the safety and tolerability of the combination of isatuximab (also known as SAR650984) and cemiplimab (also known as REGN2810) in patients with relapse/refractory multiple myeloma.

Learn more about this trial

Center Information

428 East 72nd Street
Suite 300
New York, NY 10021

Find a Specialist

Create your account today and get matched to myeloma treatment centers and specialists around the US.

  • Find centers with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new trials become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;